An Adaptive, Dose-Ranging, Phase 2 Study of Eltrekibart Given Alone or in Combination with Mirikizumab for the Treatment of Adult Patients with Moderately to Severely Active Ulcerative Colitis

Brief summary (registry, in English)

To determine whether eltrekibart alone is superior to placebo in inducing clinical remission in participants with moderately to severely active UC

What you commit to

• Study type: Interventional · Phase 2
• Planned participants: 593
• 115 sites in 14 countries
• Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of EU CTIS (euclinicaltrials.eu). It describes the study design.

AI-kivonat: who the study is looking for

Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with moderately to severely active ulcerative colitis who did not respond well to earlier treatment.

Age

18 years or older

Sex

All sexes

Disease stage

Moderately to severely active ulcerative colitis, diagnosed at least 3 months before the start.

Earlier treatment

Must have had an inadequate response, loss of response or intolerance to at least one conventional medicine (including corticosteroids) or one advanced therapy (including biologics, JAK inhibitors or S1P immunomodulators). Must be on a stable dose of certain oral UC medicines. Must not have had anti-IL-23p19 or anti-IL-12p40 antibodies before.

Main reasons for not taking part

• Past treatment with anti-IL-23p19 or anti-IL-12p40 antibodies
• A blood clot (thrombotic event) within 24 weeks before the start
• Current Crohn's disease or certain other inflammatory bowel diseases
• Certain abdominal surgeries within the past 3 months, or likely to need surgery for UC during the study
• History of certain adenomas, dysplasias or cancers

Read by machine on 9 Nov 2026.

Who cannot take part

Copied verbatim from EU CTIS (euclinicaltrials.eu) and grouped by topic. Only the trial team decides who can take part.

Who the study is looking for

Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers

Full criteria on EU CTIS (euclinicaltrials.eu)

Sites (115)

Sites in registry order. Save your city in your profile to sort them by distance.

Are you the coordinator? Confirm the details